EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Jun 29, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-06-27

Reporting Person: Lurker Nancy (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-06-27	Common Stock	M	40000	—	Acquired	135033	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-27	Restricted Stock Units	$	M	40000	Disposed		Common Stock (40000)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On December 15, 2017, the reporting person was granted 120,000 restricted stock units, vesting in three equal annual installments beginning June 27, 2018.